Genetic or pharmacological inactivation of Skp2 re-sensitizes the cisplatin-resistant NSCLC cells toward cisplatin treatment, suggesting that MLKL ubiquitination by Skp2 is a potential therapeutic target to overcome NSCLC chemoresistance. Here, SKP2 is linked to non-small cell lung carcinoma.